Growth Hormone in Poor Responders to IVF Trial
|ClinicalTrials.gov Identifier: NCT01616225|
Recruitment Status : Terminated (Insufficient/slow patient recruitment)
First Posted : June 11, 2012
Last Update Posted : July 23, 2014
This study (the "Adjuvant Growth Hormone Study") is being done to see the effects of adding Growth Hormone (GH) during fertility treatment (also called in vitro fertilization or IVF). Growth Hormone is a protein that your body normally produces. Growth Hormone can act on several different organs, including the ovaries, where eggs are made. From evidence gathered from studies done by fertility doctors over the years, researchers believe that women who have not become pregnant through IVF in the past might have better results if they go on a course of Growth Hormone during the IVF treatment. However, more research needs to be done to confirm whether adding Growth Hormone is beneficial and also to find out the best time to start Growth Hormone treatment during IVF.
We hope that our Adjuvant Growth Hormone study will help answer these questions.
|Condition or disease||Intervention/treatment||Phase|
|Infertility||Drug: Saizen (Human Growth Hormone) Drug: No Saizen Control (Standard IVF Protocol)||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Adjuvant Growth Hormone in Infertile Women With Prior Poor IVF Response: a Randomized, Controlled, Open-label Study|
|Study Start Date :||June 2012|
|Estimated Primary Completion Date :||June 2015|
|Estimated Study Completion Date :||August 2015|
|Active Comparator: No Growth Hormone Supplementation||
Drug: No Saizen Control (Standard IVF Protocol)
All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
Experimental: Luteal Growth Hormone Start
Growth hormone starting in the luteal phase of the previous menstrual cycle.
Drug: Saizen (Human Growth Hormone)
Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
Experimental: Follicular Growth Hormone Start
Starting growth hormone during the follicular phase of the prior menstrual cycle.
Drug: Saizen (Human Growth Hormone)
Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
- Oocyte yield [ Time Frame: Following course of treatment (2-3 weeks) ]To assess the effect of adjuvant GH on the number of mature oocytes recovered from women undergoing COS using a GnRH antagonist protocol.
- Pregnancy rate [ Time Frame: Approximately 2 weeks following completion of treatment. ]To assess the effect of adjuvant GH on: the proportion of subjects reaching embryo transfer; embryo quality; implantation rate; clinical pregnancy rate evaluated 5 weeks after IVF/ICSI (week 7 of gestation); proportion of subjects with clinical pregnancy; mean (SD) crown-rump length 5 weeks after IVF/ICSI (week 7 of gestation); proportion of subjects with a viable fetus(es) at week 12 of gestation; proportion of subjects with live births; duration of FSH stimulation; ampules of FSH consumed; and safety.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01616225
|Canada, British Columbia|
|Pacific Centre for Reproductive Medicine|
|Burnaby, British Columbia, Canada, V5G 4X7|